Loading...

Allogene Therapeutics, Inc.

ALLO•NASDAQ
Healthcare
Biotechnology
$2.17
$-0.11(-4.82%)
U.S. Market opens in 2h 59m

Allogene Therapeutics, Inc. (ALLO) Stock Overview

Explore Allogene Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap529M
P/E Ratio-2.42
EPS (TTM)$-0.87
ROE-0.57%
Fundamental Analysis

AI Price Forecasts

1 Month$2.37
3 Months$1.17
1 Year Target$0.00

ALLO Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Allogene Therapeutics, Inc. (ALLO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 44.09, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -2.42 and a market capitalization of 529M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-4.82%
5-Day Change
-26.44%
1-Month Change
-9.58%
3-Month Change
34.78%
6-Month Change
70.87%
Year-to-Date (YTD) Change
58.39%
1-Year Change
48.63%
3-Year Change
-55.17%
5-Year Change
-93.40%
All-Time (Max) Change
-91.32%

Contact Information

https://www.allogene.com
650 457 2700
210 East Grand Avenue, South San Francisco, CA, 94080

Company Facts

226 Employees
IPO DateOct 11, 2018
CountryUS
Actively Trading

Frequently Asked Questions